CJC 1295 No DAC

Product Specifications

• CAS: 863288-34-0
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Mass: 3367.9 Da
• Purity: 99%+ (verified by HPLC)
• Appearance: White to off-white lyophilized powder

CJC 1295 No DAC vs With DAC

CJC 1295 No DAC (Modified GRF 1-29) has an active half-life of approximately 30 minutes. Each administration produces a discrete GH pulse that closely mimics the body's natural pulsatile secretion rhythm. CJC 1295 with DAC includes a Drug Affinity Complex that binds the peptide to circulating albumin, extending its half-life to 6-8 days and producing a sustained GH elevation rather than a pulse. The No DAC form is preferred in research protocols that aim to replicate natural GH pulsatility.

Storage

CJC-1295 vials must be stored in a cool, dry place away from direct sunlight. Unreconstituted CJC 1295 peptide should be kept at -20°C for long-term storage or 2-8°C for short-term use. Once reconstituted with bacteriostatic water, CJC 1295 should be refrigerated at 2-8°C and used within 28-30 days. CJC-1295/ipamorelin storage temperature post-reconstitution follows the same standard for both peptides. Do not freeze reconstituted solutions. Always follow proper aseptic technique and storage guidelines to maintain product integrity for research applications.

Solubility

CJC 1295 is freely soluble in bacteriostatic water and sterile saline. Gently swirl the vial after adding solvent. Do not vortex or shake vigorously, as this may damage the peptide structure.

Intended Use

CJC 1295 is intended for research purposes only and is not approved for human use.

What Does CJC 1295 Do? GHRH Receptor Activation and GH Stimulation

• CJC 1295 is a 29-amino acid GHRH analogue incorporating four strategically placed amino acid substitutions that significantly increase its resistance to enzymatic degradation compared to native GHRH(1-29). It acts by selectively binding to and activating GHRH receptors in the anterior pituitary, triggering the synthesis and pulsatile release of growth hormone.
• Pharmacological research on CJC-1295 demonstrates dose-dependent increases in mean GH concentrations ranging from 2-10-fold above baseline, accompanied by IGF-1 elevations of 1.5-3-fold. These findings establish CJC 1295 peptide as a potent activator of the somatotropic axis.
• Sermorelin vs CJC 1295: sermorelin is a 29-amino acid fragment matching the native GHRH sequence, while CJC 1295 includes four stabilizing amino acid substitutions that produce a more enzymatically resistant and longer-acting molecule. Research shows CJC-1295 generates a more robust and sustained GH pulse than sermorelin at equivalent doses.

CJC 1295 Ipamorelin: The Most Studied GH Combination Stack

• The CJC 1295 ipamorelin combination is the most studied dual-peptide GH stack in preclinical research. CJC-1295 activates GHRH receptors via the adenylyl cyclase/cAMP signaling pathway, while ipamorelin activates GHS-R (ghrelin receptors) via the phospholipase C/calcium pathway. Both pathways converge on GH secretion from pituitary somatotrophs, producing a synergistic release.
• Research on combined GHRH and GHRP administration consistently shows a GH pulse that substantially exceeds what either compound achieves independently. CJC 1295 ipamorelin benefits in preclinical models include amplified GH pulse amplitude, elevated IGF-1, and measurable effects on lean mass and body composition markers.

CJC 1295 Benefits for Muscle Growth and Body Composition

• CJC 1295 for muscle growth is one of the primary research applications of GHRH analogues. Elevated GH drives hepatic production of IGF-1, which activates the PI3K/Akt/mTOR signaling cascade in skeletal muscle, a well-characterized pathway responsible for muscle protein synthesis and lean mass development.
• Preclinical research demonstrates that sustained GHRH analogue administration produces measurable increases in lean body mass and circulating IGF-1 in animal models, supporting CJC 1295 benefits for body composition research across multiple model systems.
• CJC 1295 ipamorelin results in combination research show compound effects on body composition that exceed monotherapy findings, with CJC 1295 ipamorelin results timeline typically showing measurable IGF-1 and body composition changes within 4-6 weeks of consistent administration in animal models.

CJC 1295 Dosage for Research

CJC 1295 dosage used in preclinical and pharmacological research varies by study design, animal model, and administration route. Common dosing protocols in published literature include:

• Subcutaneous injection: 100-300 mcg per administration, once to twice daily. The most common route in published research, timed to replicate natural pulsatile GH release patterns. Typically administered in the abdomen or dorsal flank in animal models.
• Intraperitoneal injection: Used in rodent studies for systemic delivery where consistent plasma concentrations are needed. Common in pharmacokinetic and dose-response studies.
• Intravenous injection: Used in some pharmacokinetic studies to establish baseline bioavailability and half-life data, particularly when comparing No DAC and DAC forms.

CJC 1295 dosage and timing in research protocols commonly targets administration in a fasted state or prior to rest cycles to maximize GH pulse amplitude, consistent with the natural suppression of GH secretion during fed states. A peptide calculator can help scale published mcg/kg doses to a given research subject weight.

CJC-1295 and Ipamorelin Dosage in Combined Research Protocols

When CJC-1295 and ipamorelin are studied together, each peptide is typically dosed independently at its own published range and administered together once or twice daily via subcutaneous injection. The combination leverages synergistic GH release through simultaneous activation of the GHRH receptor (CJC-1295) and the GHS-R ghrelin receptor (ipamorelin), producing a GH pulse substantially greater than either compound achieves alone.

Research Protocol Notes

This product is intended for research purposes only and should not be used for human consumption. It is strictly designated for laboratory and scientific use by qualified professionals. Common research applications include:

• In vitro cellular assays and cell culture studies
• Receptor binding profiling and signaling pathway analysis
• Analytical reference standards for High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS)
• Approved in vivo animal modeling to investigate physiological mechanisms and metabolic responses